Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
BUSINESS
Sun Pharma Poised to Raise Profile in Japan Dermatology Space, Generics and New Drugs Alike
Sun Pharmaceutical Industries is set to boost its presence in Japan as a specialty pharma in dermatology, regardless of the type of products - whether it be brand-name drugs or generics - looking to eventually make a foray into the…
To read the full story
Related Article
- Sun Pharma Japan to Boost Sales Force, Development to Achieve 1.5-Fold Sales Growth by 2025
October 27, 2021
- Pola Orbis to Transfer All Shares of Pola Pharma to Sun Pharma Global, Aiming to Focus on Beauty Care Business
November 28, 2018
- Sun Taps Mitsubishi Tanabe to Distribute Novartis’ 14 Established Brands
September 7, 2016
- Novartis to Sell 14 Long-Listed Brands to Sun Pharma in Japan, Likely to Stop Aredia Sales
April 1, 2016
BUSINESS
- BMS Taps Ex-Lilly Exec Katsuma as Japan Chief, Sugino as Asia-Pacific GM
January 7, 2025
- Biogen Japan Chief Hopes to Build Momentum in ALS Space Riding on Success with Qalsody
January 7, 2025
- Astellas’ Gastric Cancer Med Vyloy Approved in China
January 7, 2025
- Otsuka/Ionis’ HAE Drug Now under European Review
January 7, 2025
- J&J Bags Kaken’s STAT6 Inhibitor, Set to Take 6% Stake in Japan Firm
December 27, 2024
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…